News & Events
			

  BioControl Launches International, Multi-Center, Clinical Study of the CardioFit™ System for Heart Failure in Europe, Israel and Australia (January, 2007)  
  A new way of looking at diseased lungs (December, 2006)  
  Trig Medical Ltd. Picks up Frost & Sullivan Technology Innovation (November, 2006)  
  Can-Fite presents results showing a correlation (November, 2006)  
  Can-Fite Out Licenses Rights for its Drug (September, 2006)  
  Can-Fite BioPharma Received Israeli MoH Approval (September, 2006)  
  Can-Fite Initiated Phase IIb Clinical Trials in Rheumatoid Arthritis Patients (July, 2006)  
  214 TIMES OVERSUBSCRIBED Can-Fite Biopharma Concluded a NIS 30 Million Fund-raising for Funding Clinical Studies and Ongoing R&D (May, 2006)  
  American Medical Systems Acquires Implantable Electrical Stimulation Platform Technology from BioControl Medical. (April, 2006)  
  Stryker Announces Acquisition of Sightline Technologies Ltd. (March, 2006)  
  Deep Breeze VRI featured in Technology Watch section of International Hospital Equipment and Solutions Nov 2005 (March, 2006)  
  Can-Fite BioPharma Signed a Cooperative Research and Development Agreement (CRADA) with the US National Institute of Health (NIH)( January , 2006)  
  TransPharma Medical article in Drug Delivery Technology (January, 2006)  
  מניית כן-פייט תיכלל במדד תל-טק של הבורסה לניירות ערך בתל-אביב, החל מה-1 בינואר 2006( December , 2005)  
  Data Demonstrating Positive Activity of CF101 in Rheumatoid Arthritis Patients will be Presented in the Forthcoming Annual Scientific Meeting of the American College of Rheumatology( November, 2005)  
  Procognia awarded 2005 Frost & Sullivan Competitive Strategy Leadership Award for success in providing innovative protein array technologies ( 22 September, 2005)  
  Deep Breeze-Improving Diagnosis of Respiratory Diseases, Leading to Better Patient Care ( 14 September, 2005)  
  Colbar completes $7.25 million round led by Vitalife.( 7 September, 2004)  
  Can-Fite Seals Its Commitment To Relocate To The U.S.( 14 July  2004)  

                 
 Can-Fite Initiates Phase I Multi-Center Trial of CF101 in Combination 
with Chemotherapy for Various Solid Tumors at Harvard Medical School 
 (30 June 2004)  
	
 Can-Fite Announces Interim Results of Phase II Study of CF101 for the Treatment of Colorectal Cancer in a Late Breaking Abstract Presentation at AACR in Orlando 
Preliminary results show that CF101 is safe and successful in stabilizing solid tumors

(30 March  2004)  
  SighLine Technologies receives FDA approval for revolutionary device that diagnoses and treats Colon Cancer(21 March  2004)  
 
 Beta-O2 completes $2 million seed round led by Vitalife (8 March  2004)  
 
Can-Fite BioPharma Research Data Shows CF101 to be Effective in Restraining the Growth of Colon, Prostate and Other Cancerous Tumors Company Primes for 2004 clinical study in the US of CF101 in Combination with Chemotherapy (JANUARY 6, 2004 )  
 
QuantomiX Introduces the QX-capsule, a Nanotechnology- based Tissue Culture Dish that Enables Direct Electron Microscopy of Fully Hydrated Cells and Other Wet Specimens
 (December 11, 2003)  
 Philips and MediGuide plan to develop world's first cath lab with medical positioning technology (16 September 2003)  
 QuantomiX Raises $3.5 million from Vitalife, Pitango Venture Capital and SFKT in second financing round (14 August 2003)  

                 
 Can-Fite BioPharma Commences Phase II Trial
of  CF101 for the Treatment of Active Rheumatoid Arthritis (23 July 2003)   

                 
 TransPharma Medical Ltd. Raises $8.9 Million in a Second Round of Financing (10 June 2003)  
	

                 
 Boston Scientific Signs Agreement for Advanced Imaging and Navigation Technology (16 may 2003)   


 Vitalife Life Sciences Ventures Closes $50 Million Fund (13 April 2003)